Sunshine Biopharma (SBFMW) Cash & Equivalents (2010 - 2026)

Sunshine Biopharma has reported Cash & Equivalents for 16 years, with the latest figure at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 14.91% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (down 14.91% YoY), and the FY2025 full-year result was $9.1 million, down 5.81% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $6.9 million, down from $9.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $41.7 million in Q2 2022, with the low at $6.9 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $16.8 million across 5 years, with a median of $13.2 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 2304.93% — and 2023, when it sank 53.53%.
• Sunshine Biopharma's Cash & Equivalents stood at $21.8 million in 2022, then dropped by 25.35% to $16.3 million in 2023, then plunged by 40.55% to $9.7 million in 2024, then decreased by 5.81% to $9.1 million in 2025, then retreated by 24.23% to $6.9 million in 2026.
• The last three Cash & Equivalents figures came in at $6.9 million (Q1 2026), $9.1 million (Q4 2025), and $9.3 million (Q3 2025), per Business Quant data.